Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Craig, David W.; O’Shaughnessy, Joyce; Kiefer, Jeffrey; Aldrich, Jessica; Sinari, Shripad; Moses, Tracy M.; Wong, Shukmei; Dinh, Jennifer; Christoforides, Alexis; Blum, Joanne L.; Aitelli, Cristi L.; Osborne, Cynthia R.; Izatt, Tyler; Kurdoglu, Ahmet; Baker, A. K.; Koeman, Julie; Bárbácioru, Cátálin; Sakarya, Onur; Vega, Francisco; Siddiqui, Asim; Hoang, Linh Cao; Billings, Paul R.; Salhia, Bodour; Tolcher, Anthony W.; Trent, Jeffrey M.; Mousses, Spyro; Hoff, Daniel D. Von; Carpten, John D.

doi:10.1158/1535-7163.22498342

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Historically, these outliers have not been paid much attention, but with the advent of whole exome or whole genome sequencing (WES, WGS), interest in mechanisms responsible for the remarkable outcomes-exceptional responders (ER)-has grown considerably. By definition, the study cohorts are composed of rare patients and are therefore small (in the low hundreds of participants [1]) or sometimes consist of single case reports [2][3][4]. The rarity of these patients has encouraged researchers to analyze highly heterogeneous groups, covering a variety of cancers and treatments [1,[5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Polygenic risk scores for autoimmune related diseases are significantly different and skewed in cancer exceptional responders

Chen

Tan

Perry

et al. 2023

Preprint

View full text Add to dashboard Cite

A group of 54 exceptional responders (ERs) to cancer treatment across a variety of cancers and treatments were compared to typical cancer patients using previously defined polygenic risk scores (PRS) for multiple autoimmune-related diseases including type 1 diabetes, hypothyroidism, psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel (IBD) disease. Most of the ERs were not treated with checkpoint inhibitors and included a broad array of tumor types. Significantly elevated PRS scores were found between ERs relative to typical cancer patients in type 1 diabetes, hypothyroidism, and psoriasis. IBD PRS scores were significantly decreased in the ERs.

show abstract

Section: Introductionmentioning

confidence: 99%

Polygenic risk scores for autoimmune related diseases are significantly different and skewed in cancer exceptional responders

Chen

Tan

Perry

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Abstract: <p>XLSX file - 607K, Outlier differential expression results in mTNBC for select cancer related genes</p>

Cited by 1 publication

References 0 publications

Polygenic risk scores for autoimmune related diseases are significantly different and skewed in cancer exceptional responders

Polygenic risk scores for autoimmune related diseases are significantly different and skewed in cancer exceptional responders

Contact Info

Product

Resources

About